NHGRI will fund pilot studies using innovative molecular technologies, beyond standard DNA sequencing, to identify genes or variants causing rare genetic disorders, with applications opening in 2026.
Funding support available to study and prove effectiveness of potential neurotherapeutic agents for neurological disorders towards further development.
Encourages translational activities and small clinical studies for neural devices to address disorders affecting the nervous system; includes prototype development, safety testing, and clinical validation.
This grant supports research to optimize and advance genomic and biologic therapies for Alzheimer’s-related dementias, from preclinical development through early clinical evaluation.
Funds clinical trials for new treatments or labeling changes for rare neurodegenerative diseases in adults and children, aiming to increase FDA-approved therapies.